- AU$17.53m
- AU$12.37m
- AU$6.07m
- 66
- 18
- 51
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.67 | ||
| Price to Tang. Book | 2.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.49 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -109.04% | ||
| Return on Equity | -95.95% | ||
| Operating Margin | -186.03% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 3.94 | 8.34 | 5.75 | 5.45 | 6.07 | n/a | n/a | 44.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in the discovery and development of treatments for cancer and inflammation. The Company has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. It is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.
Directors
- Frederick Bart NEC (66)
- Graham Kelly NED (70)
- Peter Marks NVC (65)
- Shawn Van Boheemen CFO
- Jeanette Bell COO
- Alexander Hunter OTH
- David Franks SEC
- Boris Patkin NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 27th, 2015
- Public Since
- August 9th, 2016
- No. of Shareholders
- 3,742
- No. of Employees
- 1,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 292,237,950
- Address
- Suite 71, 159 Ridgecrop Drive, CASTLE HILL, 2154
- Web
- https://www.noxopharm.com/
- Phone
- +61 291442223
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for NOX
Similar to NOX
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
FAQ
What is the Noxopharm share price?
As of Today at 19:16 UTC, shares in Noxopharm are trading at AU$0.06. This share price information is delayed by 15 minutes.
How has the Noxopharm share price performed this year?
Shares in Noxopharm last closed at AU$0.06 and the price had moved by -9.09% over the past 365 days. In terms of relative price strength the Noxopharm share price has underperformed the ASX All Ordinaries Index by -13.04% over the past year.
What are the analyst and broker recommendations for Noxopharm?
The overall consensus recommendation for Noxopharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Noxopharm dividend yield?
Noxopharm does not currently pay a dividend.
Does Noxopharm pay a dividend?
Noxopharm does not currently pay a dividend.
When does Noxopharm next pay dividends?
Noxopharm does not currently pay a dividend.
How do I buy Noxopharm shares?
To buy shares in Noxopharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Noxopharm?
As of the previous close price of AU$0.06, shares in Noxopharm had a market capitalisation of AU$17.53m.
Where are Noxopharm shares listed?
Here are the trading details for Noxopharm:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NOX
What kind of share is Noxopharm?
Based on an overall assessment of its quality, value and momentum Noxopharm is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Noxopharm share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Noxopharm share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Noxopharm. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -49.14%.
As of the last closing price of AU$0.06, shares in Noxopharm were trading -12.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Noxopharm PE Ratio?
The Noxopharm PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Noxopharm?
Noxopharm's management team is headed by:
- Frederick Bart - NEC
- Graham Kelly - NED
- Peter Marks - NVC
- Shawn Van Boheemen - CFO
- Jeanette Bell - COO
- Alexander Hunter - OTH
- David Franks - SEC
- Boris Patkin - NED